Rituximab therapy for autoimmune haematological diseases

European Journal of Internal Medicine

Volumn 22, Issue 3, 2011, Pages 220-229

  Barcellini, Wilma ^a   Zanella, Alberto ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Acquired haemophilia; Autoimmune haemolytic anaemia; Cold haemagglutinin disease; Primary immune thrombocytopenia; Rituximab; Thrombotic thrombocytopenic purpura

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALEMTUZUMAB; AZATHIOPRINE; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; DEXAMETHASONE; GLUCOCORTICOID; HEMOGLOBIN; IMMUNOGLOBULIN; INTERFERON; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB; STEROID; VINCRISTINE;

ABDOMINAL ABSCESS; ABDOMINAL BLEEDING; ACQUIRED HEMOPHILIA; ACUTE BIVENTRICULAR CARDIOGENIC SHOCK; AGE; ANAPHYLAXIS; ANTIBODY TITER; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMATOLOGICAL DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; CARDIOGENIC SHOCK; CHILL; CLINICAL EFFECTIVENESS; COLD HEMAGGLUTININ DISEASE; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEVER; GRAM NEGATIVE INFECTION; HEALTH CARE COST; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HEMOPHILIA; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LOW DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; NEUTROPENIA; PLASMAPHERESIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; REMISSION; REPEATED DRUG DOSE; RETREATMENT; REVIEW; SEPSIS; SERUM SICKNESS; SINGLE DRUG DOSE; SPLENECTOMY; SURGICAL INFECTION; THROMBOCYTE COUNT; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; UPPER AIRWAY EDEMA;

EID: 79955996011     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2010.12.016     Document Type: Short Survey

References (167)

1. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764-6.
2. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3:944-50. (Pubitemid 35154008)
3. Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med 2000;192:475-82. (Pubitemid 30666248)
4. Yu S, Maiti PK, Dyson M, Jain R, Braley-Mullen H. B cell-deficient NOD.H-2 h4 mice have CD4+CD25+ T regulatory cells that inhibit the development of spontaneous autoimmune thyroiditis. J Exp Med 2006;203:349-58. (Pubitemid 43290844)
5. Looney RJ. Treating human autoimmune disease by depleting B cells. Ann Rheum Dis 2002;61:863-6.
6. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48:1484-92. (Pubitemid 36682354)
7. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
8. Cvetkovic R, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006;66:791-820. (Pubitemid 43778729)
9. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New Engl J Med 2004;350:2572-81. (Pubitemid 38758544)
10. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
11. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
12. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004;55:477-503. (Pubitemid 38316738)
13. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007;3:86-95.
14. Stasi R, Stipa E, Forte V, Meo P, Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002;99:3872-3. (Pubitemid 34534570)
15. Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol 2010;47:170-9.
16. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-73.
17. Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002;99:1486-8. (Pubitemid 34547110)
18. Steurer M, Clausen J, Gotwald T, Gunsilius E, Stockhammer G, Gastl G, et al. Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation 2003;76:435-6. (Pubitemid 36928014)
19. Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007;48:1307-12. (Pubitemid 47079357)
20. Freim Wah SG, Folvik MR, Torp SH. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin Neuropathol 2007;26:68-73. (Pubitemid 46408582)
21. Kranick SM, Mowry EM, Rosenfeld MR. Progressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphoma. Neurology 2007;69:704-6. (Pubitemid 47256017)
22. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9:425-37.
23. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010;47:187-98.
24. Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 2010;85:174-80.
25. Bolton-Maggs PH. Idiopathic thrombocytopenic purpura. Arch Dis Child 2000;83:220-2.
26. George JN, El-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. New Engl J Med 1994;331:1207-11. (Pubitemid 24331340)
27. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86.
28. Kumar S, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. Ann Hematol 2002;81:312-9. (Pubitemid 36067628)
29. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549-54.
30. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104:2623-34. (Pubitemid 39434940)
31. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008;14:149-69. (Pubitemid 351406218)
32. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. New Engl J Med 2002;346:995-1008.
33. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005;106:2244-51. (Pubitemid 41510792)
34. Nakhoul IN, Kozuch P, Varma M. Management of adult idiopathic thrombocytopenic purpura. Clin Adv Hematol Oncol 2006;4:136-44.
35. Stasi R, Newland A, Thornton P, Pabinger I. Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. Ann Hematol 2010;89:1185-95.
36. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol 2006;81:19-25. (Pubitemid 43077209)
37. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113:2161-71.
38. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641-8.
39. Schweizer C, Reu FJ, Ho AD, Hensel M. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab. Ann Hematol 2007;86:711-7. (Pubitemid 47337933)
40. Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann Hematol 2007;86:871-7.
41. Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008;112:999-1004.
42. Alasfoor K, Alrasheed M, Alsayegh F, Mousa SA. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP). Ann Hematol 2009;88:239-43.
43. Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, et al. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med 2009;266:484-91.
44. Kelly K, Gleeson M, Murphy PT. Slow responses to standard dose rituximab in immune thrombocytopenic purpura. Haematologica 2009;94:443-4.
45. Arnold DM, Dentali F, Crowther M, Meyer R, Cook R, Sigouin C, et al. Systemic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-33. (Pubitemid 351650318)
46. Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010;115:2755-62.
47. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952-7.
48. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125:232-9. (Pubitemid 38534976)
49. Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005;78:275-80. (Pubitemid 40471119)
50. Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006;107:2639-42.
51. Parodi E, Nobili B, Perrotta S, Rosaria Matarese SM, Russo G, Licciardello M, et al. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. Int J Hematol 2006;84:48-53. (Pubitemid 44756776)
52. Penalver FJ, Jimenez-Yuste V, Almagro M, Alvarez-Larran A, Rodriguez L, Casado M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 2006;85:400-6.
53. Giagounidis AA, Anhuf J, Schneider P, Germing U, Sohngen D, Quabeck K, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002;69:95-100. (Pubitemid 35178108)
54. Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 2008;50:822-5. (Pubitemid 351354792)
55. Zaja F, Vianelli N, Sperotto A, Patriarca F, Tani M, Marin L, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 2003;44:1951-5. (Pubitemid 37369630)
56. Taube T, Schmid H, Reinhard H, Von Stackelberg A, Overberg US. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica 2005;90:281-3. (Pubitemid 40293304)
57. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003;78:1340-6. (Pubitemid 37337779)
58. Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, et al. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003;88:538-46. (Pubitemid 36648443)
59. Wang J, Wiley JM, Luddy R, Greenberg J, Feuerstein MA, Bussel JB. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 2005;146:217-21. (Pubitemid 40202812)
60. Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007;92:1695-8. (Pubitemid 350248251)
61. Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol 2010;85:329-34.
62. Saleh MN, Gutheil J, Moore M, Bunch PW, Butler J, Kunkel L, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000;27:99-103. (Pubitemid 32164602)
63. Khellaf M, Le Moine JG, Poitrinal P, Francesconi C, Haddad A, Bierling P, et al. Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis. Ann Hematol 2010 [Epub ahead of print].
64. Pérez-Calvo JI, Ruiz-Ruiz F, Amores B, Torralba MA. Long-term cost-efficacy of rituximab in immune thrombocytopenic purpura. QJM 2005;98:839-40. (Pubitemid 41631336)
65. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol 2002;69:258-71. (Pubitemid 34259848)
66. Petz LD, Garratty G. Immune hemolytic anemias. New York: Churchill Livingstone; 2004.
67. Valent P, Lechner K. Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review. Wien Klin Wochenschr 2008;120:136-51. (Pubitemid 351487262)
68. Newland A, Provan D, Myint S. Preventing severe infection after splenectomy. BMJ 2005;331:417-8. (Pubitemid 41176375)
69. King KE, Ness PM. Treatment of autoimmune hemolytic anemia. Semim Hematol 2005;42:131-6. (Pubitemid 41019441)
70. Petz LD. Treatment of autoimmune hemolytic anemias. Curr Opin Hematol 2001;8:411-6. (Pubitemid 33032925)
71. Conley CL, Lippman SM, Ness P. Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency. JAMA 1980;244:1688-90.
72. Friedmann AM, King KE, Shirey RS, Resar LM, Casella JF. Fatal autoimmune hemolytic anemia in a child due to warm-reactive immunoglobulin Mantibody. J Pediatr Hematol Oncol 1998;20:502-5. (Pubitemid 29133212)
73. Nowak-Wegrzyn A, King KE, Shirey RS, Chen AR, McDonough C, Lederman HM. Fatal warm autoimmune hemolytic anemia resulting from IgM autoagglutinins in an infant with severe combined immunodeficiency. J Pediatr Hematol Oncol 2001;23:250-2. (Pubitemid 32524931)
74. Arndt PA, Leger RM, Garratty G. Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies. Transfusion 2009;49:235-42.
75. Bussone G, Ribeiro E, Dechartres A, Viallard JF, Bonnotte B, Fain O, et al. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol 2009;84:153-7.
76. Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, Gallur L, Jarque I, Caballero D, et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol 2010;89:1073-80.
77. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:1511-3.
78. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003;101:3857-61. (Pubitemid 36857857)
79. Narat S, Gandla J, Hoffbrand AV, Hughes RG, Mehta AB. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 2005;90:1273-4. (Pubitemid 41375288)
80. Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 2006;91:460-6.
81. Schöllkopf C, Kjeldsen L, Bjerrum OW, Mourits-Andersen HT, Nielsen JL, Christensen BE, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 2006;47:253-60. (Pubitemid 43084563)
82. D'Arena G, Califano C, Annunziata M, Tartarone A, Capalbo S, Villani O, et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. Eur J Haematol 2007;79:53-8. (Pubitemid 47000611)
83. Gupta N, Kavuru S, Patel D, Janson D, Driscoll N, Ahmed S, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002;16:2092-5. (Pubitemid 35203453)
84. Trapè G, Fianchi L, Lai M, Laurenti L, Piscitelli R, Leone G, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica 2003;88:223-5. (Pubitemid 37101503)
85. D'Arena G, Laurenti L, Capalbo S, D'Arco AM, De Filippi R, Marcacci G. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006;81:598-602. (Pubitemid 44066170)
86. Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004;103:2925-8. (Pubitemid 38451661)
87. Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L, Herrera-Garza JL, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood 2010 [Epub ahead of print].
88. Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Battista M, Di Bona E, et al. Lowdose rituximab in idiopathic autoimmune haemolytic anaemia. Haematologica 2010;95:204 (abstract 503).
89. Norton A, Roberts I. Management of Evans syndrome. Br J Haematol 2006;132:125-37.
90. Bader-Meunier B, Aladjidi N, Bellmann F, Monpoux F, Nelken B, Robert A, et al. Rituximab therapy for childhood Evans syndrome. Haematologica 2007;92: 1691-4. (Pubitemid 350248250)
91. Rodella E, Pacquola E, Bianchini E, Ramazzina E, Paolini R. Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome. Blood Coagul Fibrinolysis 2008;19:315-8. (Pubitemid 351670417)
92. Kittaka K, Dobashi H, Baba N, Iseki K, Kameda T, Susaki K, et al. A case of Evans syndrome combined with systemic lupus erythematosus successfully treated with rituximab. Scand J Rheumatol 2008;37:390-3.
93. Tamimoto Y, Horiuchi T, Tsukamoto H, Otsuka J, Mitoma H, Kimoto Y, et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology 2008;47:821-7 (Oxford).
94. Rückert A, Glimm H, Lübbert M, Grüllich C. Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up. Lupus 2008;17: 757-60.
95. Michel M, Chanet V, Dechartres A, Morin AS, Piette JC, Cirasino L, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood 2009;114:3167-72.
96. Collins P, Baglin T, Brown S, Dolan G, Hanley J, Keeling D, et al. UKHCDO acquired haemophilia study: a complete national cohort. Blood 2005;106:98a (Abstract 322).
97. Boggio LN, Green D. Acquired hemophilia. Rev Clin Exp Hematol 2001;5:389-404. (Pubitemid 34947697)
98. Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematol Am Soc Hematol Educ Program 2006:432-7.
99. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981;45:200-3. (Pubitemid 11081028)
100. Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987;147:1077-81.
101. Sallah S, Aledort L. Treatment of patients with acquired inhibitors. J Thromb Haemost 2005;3:595-7.
102. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006;133:591-605. (Pubitemid 43742773)
103. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review andmeta-analysis focused on therapy and prognostic factors. Br J Haematol 2003;121:21-35. (Pubitemid 36461264)
104. Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol 2007;63:47-52. (Pubitemid 46824066)
105. Machado P, Raya JM, Martín T, Morabito L, Brito ML, Rodríguez-Martín JM. Successful response to rituximab in two cases of acquired haemophilia refractory to standard-therapy. Int J Hematol 2008;87:545-9.
106. Cretel E, Jean R, Chiche L, Durand JM. Successful treatment with rituximab in an elderly patient with acquired factor VIII inhibitor. Geriatr Gerontol Int 2009;9:197-9.
107. Dedeken L, St-Louis J, Demers C, Meilleur C, Rivard GE. Postpartum acquired haemophilia: a single centre experience with rituximab. Haemophilia 2009;15:1166-8.
108. Wermke M, von Bonin M, Gehrisch S, Siegert G, Ehninger G, Platzbecker U. Successful eradication of acquired factor-VIII-inhibitor using single low-dose rituximab. Haematologica 2010;95:521-2.
109. Ichikawa S, Kohata K, Okitsu Y, Suzuki M, Nakajima S, Yamada MF. Acquired hemophilia A with sigmoid colon cancer: successful treatment with rituximab followed by sigmoidectomy. Int J Hematol 2009;90:33-6.
110. Braunert L, Bruegel M, Pfrepper C, Thiery J, Niederwieser D, S40-S43. Rituximab in the treatment of acquired haemophilia A in a patient with polymyalgia rheumatica. Hamostaseologie 2010;30:S40-3.
111. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004;103:4424-8. (Pubitemid 38745966)
112. Aggarwal A, Grewal R, Green RJ, Boggio L, Green D, Weksler BB, et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia 2005;11:13-9. (Pubitemid 40253762)
113. Kain S, Copeland TS, Leahy MF. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). Br J Haematol 2002;119:578. (Pubitemid 35365520)
114. Abdallah A, Coghlan DW, Duncan EM, Chunilal SD, Lloyd JV. Rituximab-induced long-term remission in patients with refractory acquired hemophilia. J Thromb Haemost 2005;3:2589-90. (Pubitemid 41727181)
115. Santoro C, Rago A, Biondo F, De Propris MS, De Vellis A, Guarini A, et al. Efficacy of rituximab treatment in postpartum acquired haemophilia A. Haemophilia 2007;14:147-9.
116. Field JJ, Fenske TS, Blinder MA. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia 2007;13:46-50. (Pubitemid 46002344)
117. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002;100:3426-8. (Pubitemid 35217098)
118. Fischer KG, Deschler B, Lübbert M. Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses. Blood 2003;101:3753-4.
119. Jy W, Gagliano-DeCesare T, Kett DH, Horstman LL, Jimenez JJ, Ruiz-Dayao Z, et al. Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab. Acta Haematol 2003;109:206-8. (Pubitemid 36829022)
120. Clatworthy MR, Jayne DR. Acquired hemophilia in association with ANCA-associated vasculitis: response to rituximab. Am J Kid Dis 2006;47:680-2.
121. Maillard H, Launay D, Hachulla E, Goudemand J, Lambert M, Morell-Dubois S, et al. Rituximab in postpartum-related acquired hemophilia. Am J Med 2006;119:86-8.
122. Huth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009;94:566-75.
123. George JN, Sadler JE, Lmmle B. Platelets: thrombotic thrombocytopenic purpura. Hematol Am Soc Hematol Educ Program 2002:315-34.
124. Moake JL. Thrombotic microangiopathies. New Engl J Med 2002;22:589-600.
125. Veyradier A, Meyer D. Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost 2005;3:2420-7. (Pubitemid 41727157)
126. Crowther MA, George JN. Thrombotic thrombocytopenic purpura: 2008 update. Cleve Clin J Med 2008;75:369-75.
127. Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003;14:1072-81.
128. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematol Am Soc Hematol Educ Program 2004: 407-23.
129. Lämmle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005;3:1663-75. (Pubitemid 41716552)
130. Mannucci PM, Peyvandi F. TTP and ADAMTS13: when is testing appropriate? Hematol Am Soc Hematol Educ Program 2007:121-6.
131. George JN. How I treat patients with thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Blood 2000;96:1223-9. (Pubitemid 30658447)
132. Brunskill SJ, Tusold A, Benjamin S, Stanworth SJ, Murphy MF. A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Trans Med 2007;17:17-35. (Pubitemid 46239348)
133. Rizvi MA, Vesely SK, George JN, Chandler L, Duvall D, Smith JW, et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion 2000;40:896-901.
134. McMinn Jr JR, Thomas IA, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in thrombotic thrombocytopenic purpurahemolytic uremic syndrome: a study of 78 additional patients. Transfusion 2003;43:415-6. (Pubitemid 36351137)
135. Kappers-Klunne MC, Wijermans P, Fijnheer R, Croockewit AJ, Van Der Holt B, De Wolf JT, et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2005;130:768-76. (Pubitemid 43906650)
136. Outschoorn UM, Ferber A. Outcomes in the treatment of thrombotic thrombocytopenic purpura with splenectomy: a retrospective cohort study. Am J Hematol 2006;81:895-900. (Pubitemid 44864446)
137. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005;106:1932-7. (Pubitemid 41291703)
138. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007;136:451-61. (Pubitemid 46046304)
139. Elliott MA, Heit JA, Pruthi RK, Gastineau DA, Winters JL, Hook CC. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol 2009;83:65-72.
140. Ling HT, Field JJ, Blinder MA. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol 2009;84:418-21.
141. Jasti S, Coyle T, Gentile T, Rosales L, Poiesz B. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher 2008;23:151-6.
142. Chemnitz JM, Uener J, Hallek M, Scheid C. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol 2010;89:1029-33.
143. Caramazza D, Quintini G, Abbene I, Coco LL, Malato A, Di Trapani R, et al. Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome. Blood Trans 2010;8:203-10.
144. Heidel F, Lipka DB, Von Auer C, Huber C, Scharrer I, Hess G. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 2007;97:228-33. (Pubitemid 46592142)
145. Kameda T, Dobashi H, Kittaka K, Susaki K, Yamaoka G, Arai K, et al. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment. Clin Rheumatol 2007;26:2159-62. (Pubitemid 350120360)
146. Reddy PS, Deauna-Limayo D, Cook JD, Ganguly SS, Blecke C, Bodensteiner DC, et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 2005;84:232-5. (Pubitemid 40425069)
147. Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 2002;71:105-8.
148. Chow KV, Carroll R, Branley P, Nicholls K, Becker G, Hogan C. Anti-CD20 antibody in thrombotic thrombocytopenic purpura refractory to plasma exchange. Intern Med J 2007;37:329-32. (Pubitemid 46744093)
149. Herbei L, Venugopal P. Recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab. Clin Adv Hematol Oncol 2006;4:215-7. (Pubitemid 43949856)
150. Ahmad A, Aggarwal A, Sharma D, Dave HP, Kinsella V, Rick ME, et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 2004;77:171-6. (Pubitemid 39281865)
151. Galbusera M, Bresin E, Noris M, Gastoldi S, Belotti D, Capoferri C, et al. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood 2005;106:925-8. (Pubitemid 41076435)
152. Patino W, Sarode R. Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura. J Clin Apher 2007;22:17-20. (Pubitemid 46407056)
153. Boctor FN, Smith JA. Timing of plasma exchange and rituximab for the treatment of thrombotic thrombocytopenic purpura. Am J Clin Pathol 2006;126:965. (Pubitemid 44901849)
154. Hull MJ, Eichbaum QG. Efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Clin Adv Hematol Oncol 2006;4:210-4. (Pubitemid 43949855)
155. Darabi K, Berg AH. Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol 2006;125:592-7.
156. Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost 2009;101:233-8.
157. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003;138:105-8. (Pubitemid 36222497)
158. Stein GY, Zeidman A, Fradin Z, Varon M, Cohen A, Mittelman M. Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide. Int J Hematol 2004;80:94-6. (Pubitemid 38937884)
159. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004;124:787-95. (Pubitemid 38365784)
160. Gianfaldoni G, Antonioli E, Mannelli F, Vannucchi AM, Bosi A. Chronic relapsing thrombotic thrombocytopenic purpura successfully treated with rituximab: case report. J Chemother 2005;7:449-51. (Pubitemid 41284785)
161. Kosugi S, Matsumoto M, Ohtani Y, Take H, Ishizashi H, Fujimura Y, et al. Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura. Int J Hematol 2005;81:433-6. (Pubitemid 40917689)
162. Koulova L, Alexandrescu D, Dutcher JP, O'Boyle KP, Eapen S, Wiernik PH. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Am J Hematol 2005;78:49-54. (Pubitemid 40023747)
163. Benetatos L, Vassou A, Bourantas KL. Effectiveness of rituximab as prophylaxis in thrombotic thrombocytopenic purpura. Clin Lab Haematol 2006;28:288-9. (Pubitemid 44114648)
164. Schleinitz N, Ebbo M, Mazodier K, Poullin P, Bernit E, Veit V, et al. Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS13 inhibitor. Am J Hematol 2007;82:417-8. (Pubitemid 46651158)
165. Sallah S, Husain A, Wan JY, Nguyen NP. Rituximab in patients with refractory thrombotic thrombocytopenic purpura. J Thromb Haemost 2004;2:834-6. (Pubitemid 40185722)
166. Millward PM, Bandarenko N, Chang PP, Stagg KF, Afenyi-Annan A, Hay SN, et al. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion 2005;45:1481-6. (Pubitemid 44194652)
167. Martin MG, Whitlatch NL, Shah B, Arepally GM. Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness. Am J Hematol 2007;82:679-81. (Pubitemid 47015300)